Eisenmenger Syndrome
11
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
27%
3 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (11)
Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome
A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome
Respiratory and Physical Therapy in Patients With Associated Pulmonary Arterial Hypertension (APAH) With Congenital Heart Defects
Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves
Eisenmenger Syndrome in the Nordic Countries
Sleep-disordered Breathing in Eisenmenger Syndrome
Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate
Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome
Bosentan in Treatment of Pulmonary Arterial Hypertension
Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome